3:30 pm – 4:00 pm
Please Check-in at the Registration Desk



4:00 pm – 4:08 pm
Welcome and Introductions
Carl J. Pepine, MD, MACC

Keynote Address

4:08 pm – 4:28 pm
State-of-the-Art Management of HFpEF and Glimpses into the Future
Sanjiv J. Shah, MD, FAHA, FACC, FASE
4:28 pm – 4:36 pm

Session I

4:36 pm – 4:48 pm
Coronary Microvascular Dysfunction: A Causal Mechanistic Pathway for HFpEF?
Marcelo Fernando Di Carli, MD
4:48 pm – 5:00 pm
Obesity-Related HFpEF: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2 Pathways
Sheldon E. Litwin, MD
5:00 pm – 5:12 pm
Diagnosis and Treatment of Transthyretin Cardiomyopathy: Past, Present and Future
Claudio Rapezzi, MD
5:12 pm – 5:24 pm

Session II

5:24 pm – 5:36 pm
Redefining the Standard of Care for CAD and PAD: Combining Antiplatelet Therapy with Low Dose Anticoagulation
Stuart J. Connolly, MD
5:36 pm – 5:48 pm
From Clinical Trials to Clinical Practice: Applying Cardiovascular Outcome Trial Data to T2DM Management
Darren K. McGuire, MD, MHSc
5:48 pm – 6:00 pm
Eliminating Atrial Fibrillation: Is Catheter Ablation Superior to State-of-the-Art Pharmacologic Therapy
Gerald V. Naccarelli, MD
6:00 pm – 6:12 pm

Session III

6:12 pm – 6:24 pm
Lipids, Liver, and Cardiovascular Disease
Anne Tybjaerg-Hansen, MD, DMSc
6:24 pm – 6:36 pm
Measuring Cardiovascular Risk: Remnant Cholesterol vs. LDL Cholesterol
Samia Mora, MD, MHS
6:36 pm – 6:48 pm
Omega-3 in the ASCEND, VITAL, and REDUCE-IT Trials: What Have We Learned?
Deepak L. Bhatt, MD, MPH
6:48 pm – 7:00 pm


7:00 pm – 8:00 pm
Refreshments and Networking